|
Items in cart [0] |
Questions? Call 888-624-8373 |
| Copyright © 2009. National Academy of Sciences. All rights reserved. Terms of Use and Privacy Statement |
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 63
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda
APPENDIXES
OCR for page 64
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda
This page in the original is blank.
OCR for page 65
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda
A
Agenda for the IOM Workshop ''Antiprogestins: Assessing the Science," April 13–14, 1993
APRIL 13
Room 104 Green Building 2001 Wisconsin Avenue, N.W. Washington, D.C.
8:00–8:30
Continental Breakfast, Room 110
8:30–8:45
Welcome to Participants
8:45–9:00
Purpose of the Workshop
Leslie Z. Benet, Ph.D., Chairman
Committee on Antiprogestins: Assessing the Science
9:00–10:30
SESSION I. Overview and Background: Background, Development, Mechanism of Action
9:00–9:30
Development and Future Directions in the
Development of Steroid Antagonists
Étienne-Émile Baulieu, M.D., Ph.D.
Professor of Biochemistry
School of Medicine
University of Paris-Sud
Director of Research, INSERM
9:30–10:00
Antiprogestational/Antiglucocorticoid Compounds:
Structure-Function Relationships
Nancy L. Weigel, Ph.D.
Research Associate Professor
Department of Cell Biology
Baylor School of Medicine
OCR for page 66
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda
10:00–10:30
Discussion of Session I
10:30–10:45
BREAK
10:45–2:15
SESSION II. State of the Science and Research Directions—Uses of Antiprogestins: The Reproductive Cycle
10:45–11:00
Introduction
Lynnette K. Nieman, M.D.
Senior Investigator, Deputy Clinical Director,
Special Assistant to the Scientific Director
National Institute of Child Health and Development
National Institutes of Health
11:00–11:30
Daily or Luteal Phase Administration: Mechanism of Action of the Antigestagens on the Endometrium
David T. Baird, M.D.
MRC Clinical Research Professor of Reproductive
Endocrinology
Center for Reproductive Biology
Department of Obstetrics and Gynecology
The University of Edinburgh
11:30–12:00
Uses of Antiprogestins Before 63 Days
Marc Bygdeman, M.D.
Chairman
Department of Obstetrics and Gynecology
Karolinska Institute
Stockholm
12:00–12:15
Uses of Antiprogestins After 63 Days
André Ulmann, M.D., Ph.D.
Direction; Domaine Thérapeutique Endocrinologie
Roussel-Uclaf
Romainville, France
12:15–1:30
LUNCH
1:30–1:45
Comments on Session II
David Grimes, M.D.
Professor and Vice Chair
Department of Obstetrics/Gynecology and Reproductive
Sciences
University of California at San Francisco
OCR for page 67
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda
1:45–2:15
Discussion of Session II
2:15–2:30
BREAK
2:30–4:20
SESSION III. State of the Science and Research Directions: Therapeutic Uses of Antiprogestins
2:30–3:00
Use of Antiprogestin in the Management of Endometriosis and Leiomyoma
Samuel S.C. Yen, M.D.
Professor and W.R. Persons Chair
Department of Reproductive Medicine
University of California at San Diego
3:00–3:30
Use of Antiprogestin in the Treatment of Breast Cancer
Kathryn B. Horwitz, Ph.D.
Departments of Medicine and Pathology
Division of Endocrinology
University of Colorado Health Sciences Center
3:30–3:50
Animal Models and Studies on the Mode of Action of Antiprogestins in Growth Inhibition of Mammary Tumors
David Henderson, Ph.D.
Head, Experimental Oncology
Schering AG, Berlin
3:50–4:20
Discussion of Session III
4:20–4:50
General Discussion
4:50 p.m.
Adjourn for the Day
APRIL 14
8:30–9:00
CONTINENTAL BREAKFAST (Room 110)
9:00–10:15
SESSION IV. State of the Science and Research Directions: Therapeutic Uses of Antiglucocorticoids
9:00–9:45
Lynnette K. Nieman, M.D.
Senior Investigator, Deputy Clinical Director,
Special Assistant to the Scientific Director
National Institute of Child Health and Development
National Institutes of Health
OCR for page 68
Clinical Applications of Mifepristone (RU 486) and other Antiprogestins: Assessing the Science and Recommending a Research Agenda
9:45–10:15
Discussion of Session IV
10:15–10:30
BREAK
10:30–10:50
SESSION V. Primate Models for the Study of Antiprogestins in Reproductive Medicine
Gary D. Hodgen, Ph.D.
The Howard and Georgeanna Jones Professor of
Reproductive Medicine
President, The Jones Institute Foundation
Eastern Virginia Medical School
10:50–11:00
Discussion of Session V
11:00–11:20
SUMMING UP
Paul F.A. Van Look, M.D., Ph.D.
Acting Director Special Programme of Research, Development
and Research Training in Human Reproduction
World Health Organization, Geneva
11:20–11:45
Late-Breaking Research Issues and Final Comments
11:45
ADJOURN WORKSHOP
Representative terms from entire chapter:
continental breakfast
